EJP Rare Diseases consortium awarded 1.4 M€ to validate novel treatment for rare ophthalmology conditions
The consortium is coordinated by Prof. Neil Lagali from the Institute for Biomedical and Clinical Sciences at Linköping University, Sweden
The BCDD, together with Prof. Ruth Ashery-Padan and Prof. Daniel Aberdam (INSERM), was awarded a competitive grant as part of a European consortium to find novel treatment for rare ophthalmology conditions based on the compounds discovered at the BCDD.
The consortium was funded 1.4 M€ by the European Joint Programme Rare Diseases (EJP RD), a translational initiative funded by the European Union’s Horizon 2020 program. The consortium is coordinated by Prof. Neil Lagali from the Institute for Biomedical and Clinical Sciences at Linköping University, Sweden.
The established consortium is a collaboration between researchers from Radboud University (Nijmegen, The Netherlands), University of Saarland (Homburg, Germany), INSERM (Paris, France), University of Aberdeen (Aberdeen, Scotland) and Hospital Necker- Enfants malades (Paris, France).
The project is dedicated to validate in-vitro and in-vivo novel therapeutic tools to treat or prevent progressive cornea opacification for patients suffering from progressive loss of the cornea’s transparency leading to blindness
We wish good luck to all our partners.
Related Articles
